Evidence map›Paper›PMID 38203384›Full record

ArticleInternational journal of molecular sciences2023

Antigenic Architecture of the H7N2 Influenza Virus Hemagglutinin Belonging to the North American Lineage.

Aleksandr V Lyashko, Tatiana A Timofeeva, Irina A Rudneva, Natalia F Lomakina, Anastasia A Treshchalina, Alexandra S Gambaryan, Evgenii V Sorokin, Tatiana R Tsareva, Simone E Adams, Alexey G Prilipov and 4 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Aleksandr V LyashkoThe Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, 123098 Moscow, Russia.
Tatiana A TimofeevaThe Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, 123098 Moscow, Russia.
Irina A RudnevaThe Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, 123098 Moscow, Russia.
Natalia F LomakinaThe Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, 123098 Moscow, Russia.ORCID 0000-0003-2638-4244
Anastasia A TreshchalinaFederal Scientific Center for the Research and Development of Immune-and-Biological Products, 108819 Moscow, Russia.ORCID 0000-0003-3801-2413
Alexandra S GambaryanFederal Scientific Center for the Research and Development of Immune-and-Biological Products, 108819 Moscow, Russia.ORCID 0000-0002-1892-0548
Evgenii V SorokinThe Smorodintsev Research Institute of Influenza, the Ministry of Health of the Russian Federation, 197376 St. Petersburg, Russia.
Tatiana R TsarevaThe Smorodintsev Research Institute of Influenza, the Ministry of Health of the Russian Federation, 197376 St. Petersburg, Russia.
Simone E AdamsInstitute of Microbiology, Lausanne University Hospital, 1011 Lausanne, Switzerland.ORCID 0009-0009-4120-3238
Alexey G PrilipovThe Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, 123098 Moscow, Russia.
Galina K SadykovaThe Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, 123098 Moscow, Russia.
Boris I TimofeevThe Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, 123098 Moscow, Russia.
Denis Y LogunovThe Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, 123098 Moscow, Russia.
Alexander L GintsburgThe Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of the Russian Federation, 123098 Moscow, Russia.
Ministry of Health of the Russian Federation · RUUniversity of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The North American low pathogenic H7N2 avian influenza A viruses, which lack the 220-loop in the hemagglutinin (HA), possess dual receptor specificity for avian- and human-like receptors. The purpose of this work was to determine which amino acid substitutions in HA affect viral antigenic and phenotypic properties that may be important for virus evolution. By obtaining escape mutants under the immune pressure of treatment with monoclonal antibodies, antigenically important amino acids were determined to be at positions 125, 135, 157, 160, 198, 200, and 275 (H3 numbering). These positions, except 125 and 275, surround the receptor binding site. The substitutions A135S and A135T led to the appearance of an N-glycosylation site at 133N, which reduced affinity for the avian-like receptor analog and weakened binding with tested monoclonal antibodies. Additionally, the A135S substitution is associated with the adaptation of avian viruses to mammals (cat, human, or mouse). The mutation A160V decreased virulence in mice and increased affinity for the human-type receptor analog. Conversely, substitution G198E, in combination with 157N or 160E, displayed reduced affinity for the human-type receptor analog.

Indexed as

HemagglutininsInfluenza, HumanAnimalsAntibodies, MonoclonalHumansInfluenza A Virus, H7N2 SubtypeMammalsMiceNorth AmericaAntibodies, MonoclonalHemagglutininsantigenic mappingantigenic variationescape mutantH7N2 influenza virushemagglutininmonoclonal antibodies

Identifiers

PMID38203384
PMCPMC10779424
OpenAlexW4390175970

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.